Bittensor AI Market Expands as XRP ETF Faces Valuation Headwinds

• The global animal genetics market is projected to reach $9.37 billion by 2031, driven by AI and genomic selection technologies.
• US-listed XRP spot ETFs have recorded $1.5 billion in cumulative net inflows, though total net assets have declined to $988.7 million due to token price drops.
• Thermo Fisher Scientific reported a Q2 2026 adjusted EPS of $6.03 on revenue of $11.99B, beating estimates and driving a 9.25% premarket share increase.
• Analysts maintain a moderate buy consensus for Thermo Fisher Scientific, with an average price target of $617.14.

The global animal genetics market is projected to grow from USD 6.64 billion in 2026 to USD 9.37 billion by 2031, representing a compound annual growth rate (CAGR) of 7.1%. This expansion is primarily driven by increasing global demand for animal protein and the industry's shift toward integrated genomics, precision breeding, and AI-enabled genetic improvement solutions.

Traditional approaches focused on selective breeding and basic molecular diagnostics. Modern technologies now incorporate next-generation sequencing (NGS), genomic selection, bioinformatics, and gene-editing tools like CRISPR. These advancements enable livestock producers and breeding organizations to make faster, data-driven decisions that enhance disease resistance, fertility, feed efficiency, and overall herd performance while optimizing resource utilization.

In terms of segmentation, animal genetic materials accounted for the largest share of 71.6% in 2025, supported by their extensive use in artificial insemination and embryo transfer programs. The poultry segment led the live animal category with a 32.7% share in 2025, fueled by widespread adoption of genomic selection. The PCR technology segment held the largest share at 27.7%, while diagnostic centers are projected to register the highest CAGR of 5.0% during the forecast period.

Rising pet ownership and growing awareness of inherited diseases in companion animals are accelerating demand for genetic screening, parentage verification, and breed-specific health testing. Technological advancements, including next-generation sequencing (NGS), AI-enabled breeding, genomic evaluation, and reproductive technologies, are enabling faster genetic gain and more accurate selection decisions. This trend is particularly evident in commercial dairy, beef, swine, poultry, and aquaculture production, where continuous genetic improvement is essential for meeting the growing global demand for safe, sustainable, and high-quality animal protein.

In 2025, animal semen accounted for the largest share of the animal genetic materials market. Its dominance is driven by the widespread adoption of artificial insemination (AI) across dairy cattle, beef cattle, swine, poultry, and other livestock species. Artificial insemination remains the most widely used reproductive technology due to its cost-effectiveness, ease of implementation, and ability to rapidly disseminate superior genetics across large animal populations.

By end user, the diagnostic centers segment is expected to grow at the highest CAGR during the forecast period. Growth is driven by the increasing demand for genetic disease screening, parentage verification, breed identification, genomic profiling, and trait testing across livestock and companion animals. As commercial breeding programs increasingly adopt genomic selection and precision breeding, diagnostic centers are expanding their molecular testing capabilities using technologies such as PCR, SNP genotyping, NGS, and DNA sequencing to deliver accurate and high-throughput genetic analyses.

How Are XRP ETF Inflows and Prices Diverging?

US fund data show XRP reached a new all-time high for ETF demand, with US-listed spot funds recording $1.5 billion in cumulative net inflows. The milestone has collided with a weaker price tape: total net assets across the seven products stood at $988.7 million, equal to 1.48% of XRP’s market capitalization. The difference of $511 million between lifetime inflows and current assets reflects valuation losses rather than investor redemptions, because fund holdings have continued to increase even as the token declined.

At the time of the ETF snapshot, XRP was changing hands near $1.07, about 71% below its July 2025 high of $3.66 and down more than 40% year-to-date in a bear market. Monthly creation activity has cooled sharply after an early surge: net inflows slowed from $131 million in May to $59 million in June and about $12.3 million in July, a contraction of more than 90% over two months. Six July sessions showed no net creations, and July 29 recorded only $584,710 of inflows into a Franklin Templeton product.

Bitwise leads the complex with roughly $500 million of cumulative inflows, followed by Canary Capital at $467 million and Franklin Templeton at $422.4 million; the top three issuers account for about 93% of the category’s lifetime creations. The funds collectively hold about 978.9 million XRP, less than 1% of the 100 billion maximum supply. Base-case modeling assigns a 45% probability to cumulative inflows reaching only $1.55 billion by the fourth quarter, while a legislative breakthrough could lift monthly creations above $100 million and push cumulative inflows toward $2.2 billion.

The Grayscale XRP Trust ETF is solely and passively invested in XRP. Its investment objective is to reflect the value of XRP held by the Fund, less expenses and other liabilities. XRP is a digital asset that is created and transmitted through the operations of the peer-to-peer Ripple Network, a decentralized network of computers that operates on cryptographic protocols.

The next major catalyst is the CLARITY Act, which would give XRP a statutory commodity framework. GXRP allows investors to gain exposure to XRP directly in investment accounts, accessed alongside traditional assets, while avoiding the challenges of buying, storing, and safekeeping the token directly.

Why Is Thermo Fisher Scientific Raising Guidance?

Thermo Fisher Scientific reported Q2 2026 adjusted EPS of $6.03 on revenue of $11.99B, beating estimates of $5.72 and $11.71B; shares rose 9.25% premarket. Company raised full-year 2026 guidance to $47.4B-$48.1B revenue and $24.93-$25.33 adjusted EPS, citing strengthened customer activity across markets.

Adjusted operating margin expanded 90 basis points to 22.8%; organic revenue grew 5%, driven by pharma/biotech demand and recent acquisitions. Management expects second-half organic growth to accelerate to 4% from 3% in H1, with continued strength in pharma and stabilizing academic/government markets. Company plans $4B in share buybacks and $700M in dividends for 2026; CEO cited innovation in mass spectrometry and AI-enabled tools as key growth drivers.

Recent analyst activity on Thermo Fisher Scientific (NYSE: TMO) highlights shifting institutional perspectives. Wells Fargo reduced its price target from $675.00 to $615.00 while maintaining an overweight rating. Conversely, Barclays increased its price objective from $625.00 to $650.00, also assigning an overweight rating.

Piper Sandler raised its target from $510.00 to $600.00 with a neutral rating, and Wall Street Zen upgraded its rating from hold to buy. KeyCorp reiterated an overweight rating. The consensus among analysts stands at a moderate buy, with an average price target of $617.14, supported by one strong buy, seventeen buy, and six hold ratings.

Concurrently, Compass Capital Management Inc. was reported to trim its stake in the company, signaling that while institutional sentiment is largely positive, some portfolio managers may be adjusting positions for rebalancing or risk management purposes. Thermo Fisher Scientific continues to be viewed as a critical provider of scientific instrumentation, reagents, and services, underpinning the analyst confidence in its market position.

Thermo Fisher Scientific remains a global provider of scientific instrumentation, reagents, consumables, software, and services for research, clinical, and industrial laboratories. The company's recent performance underscores the robust demand for scientific tools in both commercial and academic sectors.